About this episode

Type 2 diabetes (T2D) is among the most impactful and costly biomedical challenges confronting society. Current treatment regimens for T2D rely upon daily drug dosing and frequent glucose monitoring to normalise blood glucose levels. However, these medications can only delay disease progression and frequently have undesired side effects including hypoglycaemia and weight gain. Growing evidence supports a key role for the brain in glucose homeostasis and diabetes pathogenesis. Dr Jarrad Scarlett and his research team at the University of Washington and Seattle Children’s Hospital are working on the development of novel pharmaceuticals to target the brain to induce sustained remission of T2D.